Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Pemetrexed/Carboplatin in Non-squamous NSCLC with Brain Metastases
NCT04211090Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Intracranial Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04211090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211090.